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Abstract Mutations in PINK1 (PARK6), a serine/
threonine kinase involved in mitochondrial homeostasis,
are associated with early onset Parkinson’s disease.
Fibroblasts from Parkinson’s disease patients with com-
pound heterozygous mutations in exon 7 (c.1488 + 1G >
A; c.1252_1488del) showed no apparent signs of mito-
chondrial impairment. To elucidate changes primarily
caused by lack of funct ional PINK1, we over-
expressed wild-type PINK1, which induced a significant
downregulation of LRRK2 (PARK8). Indeed, we found
that LRRK2 protein basal levels were significantly
higher in the mutant PINK1 fibroblasts. To examine
the interaction between the two PARK genes in a
disease-relevant cell context, we generated induced plu-
ripotent stem cell (iPSC) lines from mutant, carrier and
control fibroblasts by lentiviral-mediated re-program-
ming. Efficiency of neural induction and dopamine
differentiation using a floor-plate induction protocol
was similar in all genotypes. As observed in fibroblasts,
PINK1 mutant neurons showed increased LRRK2 ex-
pression both at the RNA and protein level and transient
over-expression of wild-type PINK1 efficiently down-
regulated LRRK2 levels. Additionally, we confirmed a
dysregulation of LRRK2 expression in fibroblasts from
patients with a different homozygous mutation in PINK1
exon 4, c.926G > A (G309D). Thus, our results identify
a novel role of PINK1 modulating the levels of LRRK2
in Parkinson’s disease fibroblasts and neurons, suggest a
convergent pathway for these PARK genes, and broaden
the role of LRRK2 in the pathogenesis of Parkinson’s
disease.
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Rare monogenic forms of Parkinson’s disease (PD) have been
correlated to specific gene mutations [1], providing the oppor-
tunity to identify novel pathogenic pathways or molecular
mechanisms that may contribute to more frequent forms of
the disease [2] and to examine interactions between PARK
genes. Alternatively, early-onset genetic forms could represent
a distinct entity at the molecular level.
PD-related mutations in PINK1 (PTEN-induced kinase 1,
PARK6) compromise kinase function or protein stability [3];
thus, the phenotype is thought to result from a loss of function.
PINK1 mitochondrial localization supports its involvement in
the mitochondrial dysfunction extensively described in PD
[4], and PINK1 protects against stress-induced mitochondrial
dysfunction [3, 5]. In addition, the PINK1/Parkin signaling
pathway controls mitochondrial quality and mitophagy [6],
even if it appears that this pathway is not modified by endog-
enous human PINK1 mutations [7, 8]. Likewise, PINK1 reg-
ulates mitochondrial fusion and fission dynamics [9], al-
though the net effect of PINK1 mutations is currently a matter
of controversy because both increased fusion and increased
fission have been reported in different species [10].
LRRK2 (PARK8) is one of the genes most frequently mu-
tated in PD. LRRK2 has been implicated in a very broad range
of cellular pathways so the precise mechanisms leading to
neuronal degeneration remain to be defined [11]. An effect
of LRRK2 on mitochondrial function was described in
Caenorhabditis elegans [12]. Interestingly, in this model or-
ganism, the absence of lrk-1 rescues all phenotypic aspects of
pink-1 loss-of-function mutants. Conversely, the
hypersensitivity of lrk-1 mutant animals to stressors is reduced
in a pink-1 mutant background, suggesting antagonistic ef-
fects of lrk-1 and pink-1 [13].
With the aim to define a PINK1-related phenotype for
in vitro studies, we investigated expression pattern of genes
involved in mitochondrial dynamics and PARK genes in fibro-
blasts and induced pluripotent stem cell (iPSC)-derived dopa-
mine neurons from a PINK1-PD Spanish kindred [14]. This
led us to unveil an upregulation of LRRK2 in PINK1 mutants
and an interaction between these two PARK gene products in
human cells which were ratified in a different pedigree.
Methods
Human Samples
Skin samples were obtained from subjects expressing mutated
forms of PINK1 diagnosed at the Hospital Universitario
Insular de Gran Canaria (La Palma de Gran Canaria, Spain)
and from age-matched healthy individuals at the Hospital
Donostia and Onkologikoa (San Sebastian, Spain). PD pa-
tients presented an early-onset, typical parkinsonian syn-
drome, characteristic of PINK1-associated PD [14].
Demographic data are provided in Table 1. Three samples
from individuals from another Spanish family harboring the
G309D (c.926G > A) mutation in exon 4 [3] were also ana-
lyzed to avoid possible confounding effects caused by consan-
guinity in the first family. Dermal fibroblasts were cultivated
as described previously [15].
Table 1 Dermal fibroblast






PDP1: PINK1c.1488 + 1G > A + c.1252_1488 (PINK1-exon7/del) <55 PD
PDP2: PINK1c.1488 + 1G > A (PINK1-exon7) <55 Asymptomatic
PDP3: PINK1c.1488 + 1G > A + c.1252_1488 (PINK1-exon7/del) >55 PD
PDP4: PINK1c.1488 + 1G > A (PINK1-exon7) <55 Asymptomatic
PDP5: PINK1 G309D/G309D >55 PD
PDP6: PINK1 G309D >55 Asymptomatic
PDP7: PINK1 G309D/G309D <55 PD
The study included dermal fibroblasts from five control subjects (twomales and three females) and seven subjects
with mutations in PINK1 from two Spanish kindreds, four patients (two males and two females and three carriers
(one male and two females) [14, 20]. Fibroblasts from the PDP1, PDP2, and PDP3 individuals were
reprogrammed to obtain iPSCs lines and subsequently differentiated to dopamine neurons
PD Parkinson disease
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Protocol Approvals, Registrations, and Patient Consents
The study was approved by the Ethical Committee on the Use
of Human Subjects in Research in Euskadi, Spain. All sub-
jects gave informed consent for the study using forms ap-
proved by the ethical committees on the Use of Human
Subjects in Research at Hospital Universitario Insular de
Gran Canaria, La Palmas de Gran Canaria; Hospital
Donostia and Onkologikoa, San Sebastián; and Hospital San
Cecilio, Granada, respectively. Generation of iPSC lines was
approved by the Advisory Committee for Human Tissue and
Cell Donation and Use, Instituto Carlos III, Ministry of
Health, Spain.
Genetic Analysis
PINK1 variants were analyzed by conventional PCR using a
primer pair designed to amplify a region expanding exons 6
and 8 [14]. Total RNA and cDNAwere obtained as described
previously [15] for quantitative RT-PCR. Primer sequences
[14] are provided in Supplementary Table S1. Comparative
analysis of gene expression levels (ΔΔCt) was carried out
using GAPDH as reference. Standard G-band karyotypes of
the iPSC clones used in the study were performed at the
Policlinica Gipuzkoa (San Sebastian, Spain).
ATP Content
Cellular ATP was measured using the Luminiscent ATP
Detection kit (Abcam, Cambridge, UK). Cells were harvested,
pelleted, and washed once in PBS. An aliquot was used for
protein quantification. The rest was re-suspended in 50 μl
growth medium, and cells were lysed by adding 50 μl of the
detergent and mixing. After a 5-min incubation, 50 μl of sub-
strate was added and luminescence was quantified in a
GloMax® luminometer (Promega, Madison, WI, USA). An
ATP standard curve was prepared, and values were calculated
in picomole per microgram of protein in the cell extract.
Glycolytic Rate
The rate of glycolysis was determined in fibroblasts, seeded in
flasks, by the conversion of [3-3H] glucose into 3H2O, as
described previously [16].
Western Blotting
Whole-cell lysates were prepared in RIPA buffer with a pro-
tease inhibitor cocktail (Roche, Mannheim, Germany). SDS-
PAGE and protein transfer and blotting were carried out ac-
cording to standard procedures [15]. Primary and secondary
antibodies are listed in Supplementary Table S2. Visualization
of HRP-labeled proteins was performed using enzyme-linked
chemifluorescence (ThermoFisher Scientific, Waltham, MA,
USA) and quantified using ImageJ software. Data were nor-
malized to control in order to compare different experiments.
Immunofluorescence
Cells plated onto glass coverslips were incubated with
MitoTracker® Deep Red FM (M22426, Molecular Probes®,
Life Technologies, Carlsbad, CA, USA) for 45 min and fixed
for 10 min with 4% paraformaldehyde (15710-S, Electron
Microscopy Sciences). Immunofluorescence staining was per-
formed as previously reported [17]. Antibodies are listed in
Supplementary Table S2. Images were acquired in a Zeiss
LSM510 confocal microscope using the exact same settings
for control and experimental samples and analyzed with
ImageJ 1.42q software (NIH, http://rsb.info.nih.gov/ij).
Automatic color level correction was used when required to
enhance the contrast. Mitochondrial morphology was
classified as tubular, mixed, or round (fragmented) according
to published criteria [18]. Images were acquired at ×63 mag-
nification, and 1000–5000 cells were counted by two blinded
investigators on 16 randomly selected visual fields from at
least two independent experiments, using ImageJ. Tyrosine
hydroxylase positive neurons were counted over total ßIII-
tubulin positive neurons at day 50–70 as previously described
[17]. Live images were acquired using the Zoe™ Fluorescent
Cell Imager (BioRad, Hercules, CA, USA) at ×20.
PINK1 Over-expression
Fibroblasts at 70–90% confluence were electroporated with
the Neon® Transfection System (Invitrogen™, Waltham,
MA, USA), using two pulses of 1500 V for 20 ms, with
wild-type PINK1 (pcDNA-DEST47 PINK1 C-green fluores-
cent protein (GFP)) [19], from MR Cookson, Addgene no.
13316) or a control GFP plasmid, at 0.5 μg/106 cells.
Additional controls in each group received only the pulses.
Cells were collected for analysis at 24 and 48 h post-
transfection given that expression declined rapidly to baseline
levels after 72 h (data not shown). Electroporation in neural
cells was done following the same procedure using two pulses
of 1000 V. Neurons were collected for analysis at 4 days to
minimize the effect of the electroporation on transcriptional
changes.
iPSC and Neuronal Differentiation
Human-iPSC lines from the two Parkinson patients and one
carrier and from age-matched control individuals were derived
in our laboratory using lentiviral vectors and differentiated as
previously described [17] (see Supplementary Fig. S1). The
cell lines have been deposited in the Spanish National Cell
Bank and are available at http://www.isciii.es/ISCIII/es.
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Data Analysis and Statistics
Data analysis was carried out using GraphPad Prism software
(v. 4.0c, La Jolla, CA, USA). One-way or two-way ANOVA
with Bonferroni post-hoc tests were used to compare groups.
Student’s t test was used to detect changes in fold expression
whenever data were normalized to control levels. In all exper-
iments using human fibroblast samples, four to five control
individuals were assayed together with the two PINK1-exon7/del
patients and the two PINK1-exon7 carriers or with the two
G309D homozygous and one heterozygous carrier in at least
two independent determinations. For neuronal experiments,
data from three independent differentiations of the three mu-
tant iPSC lines were included with two to three control
pluripotent lines. In addition to the iPSC lines reprogrammed
for this study, control cell lines [17] were differentiated and
analyzed in parallel. Data in the figures represent the
mean ± SEM of two to four independent experiments. The
threshold for significance was set at p < 0.05.
Results
Characterization of Parkinson’s Disease PINK1Mutant
Fibroblasts
We established primary cultures of fibroblasts obtained from
dermal biopsies of healthy subjects and individuals carrying
Fig. 1 PINK1 mutant fibroblasts characterization. a PCR analysis and
agarose gel electrophoresis in controls, PD patients (PDP1 and PDP3),
and carriers (PDP2 and PDP4) show the exon 7 loss and an additional 33-
bp deletion in PINK1-exon7/del samples (PDP1 and PDP3). GAPDH was
used as the reference gene. b Quantitative RT-PCR determination of
PINK1 RNA levels in control (N = 4), carrier (N = 2), and patient
(N = 2) samples. Columns represent the mean ± SEM of three
independent experiments in the same samples. c ATP levels were not
different in control, carrier, and mutant fibroblasts. Scatter plot graphic
of three independent experiments. dGlycolysis flux, measured as the rate
of [3-3H] glucose incorporation into 3H2O, in control (N = 5), carrier
(N = 2), and mutant (N = 2) fibroblasts, was increased in PINK1 mutant
fibroblasts. Experiments were done in triplicate. One-way ANOVA and
post-hoc analysis *p < 0.05 and **p < 0.01. e Examples of mitochondrial
network tubularity visualized with MitoTracker® staining showing a tu-
bular and round network in the left panel and a tubular in the right one. f.
Quantification of tubularity in fibroblast samples showed no differences
between genotypes. Mitochondrial morphology was assessed in random-
ly selected fields, and >150 cells were analyzed. Columns represent the
mean ± SEM of three independent experiments. Scale bar 50 μm
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modifications in the PINK1 gene that result in the inactivation
of the normal kinase function [14]. Sample verification was
confirmed by conventional PCR analysis (Fig. 1a) that iden-
tifies the shorter transcripts corresponding to the deletion (del)
and the exon 7 skipping (-exon7) in the compound heterozy-
gous patients (PINK1-exon7/del, PDP1 and PDP3) and hetero-
zygous carriers (PINK1-exon7, PDP2 and PDP4). In spite of the
mutations, PINK1 RNA expression was similar in mutant,
carriers, and control fibroblasts (Fig. 1b). Baseline ATP levels
were not different between groups (Fig. 1c). Nevertheless,
using a sensitive method for glycolytic flux assessment, we
detected an increase in the glycolytic rate in PINK1 mutants
and carriers (Fig. 1d), as recently described in mouse Pink1
KO cells [16]. We next examined the morphology of the mi-
tochondrial network using MitoTracker®; semi-quantitative
analysis of tubularity (Fig. 1e, f) showed no differences be-
tween genotypes. This does not exclude subtle alterations in
mitochondrial morphology or function, but it is in agreement
with previous studies in fibroblasts carrying other PINK1
mutations [20]. We analyzed the expression levels of proteins
involved in mitochondrial fusion (MNF2) and fission
(DNM1L and MFF) to explore whether the lack of morpho-
logical changes in mitochondrial tubularity was due to com-
pensatory adjustments in their levels. The results are shown in
Supplementary Fig. S1 and revealed minor changes in fusion/
fission dynamics that can reflect compensatory adaptations to
the lack of PINK1 kinase function in fibroblasts. These results
are consistent with previous studies that have used human
fibroblasts to investigate disease and compensatory mecha-
nisms in genetic PD [21].
Effect of PINK1 Over-expression in Fibroblasts
To identify changes causally related to PINK1 deficiency, we
evaluated the capacity of wild-type PINK1 over-expression to
modify the gene expression profile in PINK1-exon7/del mutant
fibroblasts. Following electroporation, average PINK1 levels
determined by qPCRwere elevated, 31 ± 4.5-fold over control
Fig. 2 Over-expression of wild-type PINK1 downregulates LRRK2. a
PINK1 RNA levels analyzed by quantitative RT-PCR. Average increase
by qPCR was not different across groups (31 ± 4.5-fold increase over
mock GFP transfection). b A representative image of an agarose gel
electrophoresis showing the expression of the 499 bp band corresponding
to the exons 6 to 8 of PINK1 in the PINK1-exon7/del samples (PDP1 and
PDP3; boxed) after electroporation with PINK1.GFP. c RNA levels
analyzed by quantitative RT-PCR in fibroblasts after PINK1 over-expres-
sion. All data are expressed as fold change over mock (GFP) transfected
samples. Scatter plot graphics of two to three independent experiments in
control (N = 2), carrier (N = 2), and mutant (N = 2) fibroblasts. One-way
ANOVA. *p < 0.05 and **p < 0.01
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cells, with no differences across genotypes in two independent
experiments (Fig. 2a) and a clear expression of a 499 band
corresponding to the wild-type PINK1 exons 6–8 in
transfected mutant fibroblasts (boxed in Fig. 2b). Transient
transfection of wild-type PINK1 did not modify the levels of
genes involved inmitochondrial dynamics such as mitofusin 2
(MFN2), and the pro-fission DNM1L orMFF genes (Fig. 2c).
Likewise, there were no significant changes in DJ1 (PARK7)
or Parkin (PARK2, not shown), whereas, interestingly, we
found a significant decrease in LRRK2 (PARK8). In view of
these results, we analyzed the expression of UHRF2, an E3
ligase reported to be repressed in LRRK2G2019S mutant neu-
rons [22] and found that it was upregulated (Fig. 2d), suggest-
ing that the changes in LRRK2 expression in this paradigm are
relevant.
LRRK2 Expression in PINK1Mutant Fibroblasts
Since we identified a significant decrease in LRRK2 in PINK1
over-expression experiments, wewent on to study the baseline
expression of LRRK2 in mutant fibroblasts. LRRK2 RNAwas
elevated in PINK1-exon7/del fibroblasts although not signifi-
cantly different from the control (Fig. 3a). Although some
transcripts have been shown to increase with aging in fibro-
blasts and other tissues, we have not found any correlation
between age and LRRK2 mRNA levels in fibroblasts from
control individuals studied in our laboratory (age range 17–
63 years; R2 = 0.082, p = 0.42, data not shown). LRRK2
protein was remarkably increased in PINK1-exon7/del samples,
with no change in PINK1-exon7 fibroblasts (Fig. 3b). LRRK2
sub-cellular distribution was similar in all groups (Fig. 3c).
LRRK2 Expression in PINK1Mutant Neurons
Our findings in fibroblasts suggest that PINK1 and LRRK2
may act in a convergent pathway, with PINK1 regulating
LRRK2 expression. Thus, to identify whether LRRK2 may
be a factor contributing to the degeneration of dopamine neu-
rons in PINK1-PD, we made iPSC lines from the two PINK1-
exon7/del patients (PDP1 and PDP3 lines) and one carrier
(PDP2) (Supplementary Fig. S2 and Fig. 4a, b) .
Unfortunately, the other carrier line (PDP4) was lost due to
technical problems. Pluripotent cells were differentiated to-
wards dopaminergic neurons using an inductive protocol
combining developmental signals as described [17]
(Fig. 4c). Because significant changes in the expression of
genes and levels of proteins occur during neuronal maturation,
we analyzed cultures at two time points, corresponding to
neural progenitors (2–6 weeks) and neurons (6–12 weeks)
(Fig. 4c). There were no apparent defects either in neural
Fig. 3 LRRK2 baseline expression in fibroblasts. a LRRK2 RNA levels
by qPCR were not significantly different in control (N = 4), carrier
(N = 2), and mutant (N = 2) fibroblasts examined in triplicate. b
Representative blot and quantification of LRRK2 protein level in the
same samples showed a significant increase in PINK1 mutants
(2.49 ± 0.24; ***p < 0.001). Columns represent the mean ± SEM of
four independent experiments. c LRRK2 subcellular distribution
showed a similar pattern in all genotypes. Cells were counterstained
with phalloidin (actin, white) to visualize the cytoskeleton. Scale bar
50 μm
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induction in the mutant cells, in agreement with published
results for iPSC lines carrying homozygous point mutations
in the PINK1 gene [7, 23, 24], or in the generation of dopa-
mine neurons, with >30% of TH positive neurons in all geno-
types (Fig. 4d, e). Analysis of the mitochondrial morphology
in mature neurons showed more cells with a fragmented mi-
tochondrial network in the PINK1-exon7/del cultures (Fig. 4f).
However, RNA expression level ofMNF2,DNM1L, andMFF
were not significantly different between genotypes
(Supplementary Fig. S3).
It is known that LRRK2 expression is rather low in the
developing brain [25]. Indeed, in neural progenitors, LRRK2
RNA levels were barely detectable and there were no
differences between groups. The expression increased at the
neuronal stage, but only mutant neurons had significantly
higher LRRK2 levels than progenitors, which were also higher
than control neurons (Fig. 5a). At the protein level, the PINK1-
exon7/del mutant neurons showed increased protein levels of
LRRK2 at the neuronal stage (Fig. 5b), corroborating our
findings in fibroblasts in a disease-relevant cell context.
Over-expression of PINK1 wild-type in PINK1-exon7/del mu-
tant cells was performed at the end of neural progenitor stage
(5–6 weeks) with good survival and robust expression of the
GFP reporter 1 week after transfection (Fig. 5c) that was con-
firmed by the presence of a strong band corresponding to the
full length PCR product of exons 6–8 (Fig. 5d). Like in the
Fig. 4 PINK1 iPSC neuron characterization. a Representative bright
field images of iPSC colonies from selected clones from two
Parkinson’s disease patients (PDP1 and PDP3) and one asymptomatic
carrier (PDP2) and a control used for differentiation. Scale bar 0.5 mm.
b PCR analysis of PINK1 showed the same splicing pattern in the iPS cell
lines as in the original fibroblasts. c Schematic representation of the dif-
ferentiation protocol and the two maturation stages used for analysis. d
Confocal images show ubiquitous expression of Sox2 (red) and Nestin
(green) at the neural progenitor stage andβIII-tubulin (TuJ1, red) and TH
(green) at the neuronal stage. Scale bar 50 μm. e Quantification of TH
positive neurons (over TuJ1) at the neuronal stage showed no differences
across different cell lines in two independent experiments. f
Representative images of MitoTracker® labeling in 8-week-old neurons
from control (N = 2), carrier (N = 1), and mutant (N = 2) lines. Scale bar
10 μm. Quantification of cells presenting predominantly tubular, mixed,
or fragmented mitochondrial morphology showed that there were more
neurons with fragmented network in the mutant cultures (one-way
ANOVA and post-hoc analysis, p < 0.05)
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fibroblasts, over-expression of wild-type PINK1 induced a
marked decrease in LRRK2 expression, with no effect on the
expression of neuronal βIII-tubulin, TUBB3, other PARK
genes or mitochondrial gene expression (Fig. 5e).
To establish the relevance of LRRK2 deregulation in
PINK1 mutants, we next examined LRRK2 levels in human
fibroblasts harboring another mutation in PINK1, G309D (see
Table 1), located in exon 4, that causes a modest decrease in
kinase function with no change in protein stability [3, 19, 20].
The glycolytic rate was higher in the homozygous samples
(105.7 ± 1, N = 2) than in controls (75.4 ± 6.9, N = 3,
p < 0.05, data not shown). Fibroblasts from both PD patients
had higher LRRK2 RNA levels (Fig. 6a), although in these
samples, the protein levels were not significantly different
from control (Fig. 6b). The mitochondrial network appeared
to be normal (Fig. 6c).
Discussion
In this study, we sought to define a disease-related in vitro
phenotype in human cells with PD-associated PINK1
mutations. We did not find consistent mitochondrial alter-
ations as hypothesized but found instead a remarkable dereg-
ulation of LRRK2, revealing a previously under-recognized
connection between these two PARK genes in human cells.We
corroborated this association in fibroblasts from a second fam-
ily with a different mutation in PINK1.
Our data suggest that PINK1 exerts, directly or indirectly,
an inhibitory effect on LRRK2 at the transcriptional level.
Indeed, over-expression of wild-type PINK1 decreased
LRRK2 levels in control and mutant cells. In mutant fibro-
blasts and neurons, LRRK2 deregulation resulted in increased
LRRK2 protein level.
Abnormal protein synthesis, cytoskeletal dynamics, and
mitochondrial transport have all been implicated in LRRK2
pathogenesis [26]. Studies in C. elegans [12] and Drosophila
[27] suggest an antagonistic effect of lrk-1 and pink-1 [13]
with clear, if complex, interactions between these two genes,
not unlike in our study.
In agreement with previous studies [8, 20, 28], PINK1-
patient fibroblasts showed only subtle signs of mitochondrial
dysfunction with normal levels of ATP—at the expense of an
increased glycolytic rate—and no conspicuous alterations in
Fig. 5 LRRK2 increase in PINK1 iPSC-derived neurons. a LRRK2RNA
levels significantly increased in PINK1mutants from the progenitor (NP)
to the neuronal (N) stage (two-way ANOVA, p < 0.05) and were higher in
mutants than in control neurons (p < 0.05) bRepresentativeWestern blots
and corresponding quantification of LRRK2 protein levels at NP and N
stages showed a significant increase in the mutant neurons (p < 0.01). c
Live images of GFP immunofluorescence in PINK1 mutant NP (in vitro
day 35) 6 days after electroporation with wild-type PINK1.GFP. Scale
bar 60 μm. d Representative image of an agarose gel electrophoresis
showing the over-expression of the 499 bp band corresponding to the
wild-type PCR product (exons 6–8) of PINK1 in electroporated control
and PINK1-exon7/del neurons (PDP3). Average PINK1 increase by qPCR
was not different across groups. e qPCR analysis in three independent
over-expression experiments showed a significant downregulation of
LRRK2 (a decrease of 60 ± 9.6% over GFP mock transfection;
p < 0.05), without inducing any significant changes in fusion/fission
genes, PARK7 and PARK2, or βIII-tubulin (TUBB3) expression
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the mitochondrial network. Similar findings have been docu-
mented for other PARK genes, like Parkin [29] and LRRK2
[30]. The net effect of PINK1 kinase deficiency on fusion/
fission dynamics is a matter of controversy as different model
organisms show opposite effects (increased tubularity or in-
creased fission) [10]. It is worth noting that there are remark-
able differences between vertebrate (mouse and zebrafish) and
invertebrate (fly and worm) models regarding the effects of
PARK genes on mitochondrial dynamics. Analysis of proteins
involved in fusion and fission mitochondrial dynamics in PD
fibroblasts showed alterations that are consistent with activa-
tion of compensatory mechanisms in the mutants but could
also reflect a defective inhibition of fission through TRAP1
[31, 32].
Recent studies have proposed patient fibroblasts as an ad-
equate system to investigate diseasemechanisms and compen-
satory pathways in genetic PD [21], but we took advantage of
reprogramming technology to generate iPSC and neurons
from these patients and validate our findings in a disease-
relevant cell type. iPSC-derived neurons offer the benefit of
preserving cell-type specific endogenous expression and tran-
scriptional regulation of the mutated gene. While modeling a
complex, age-related and mostly sporadic disorder such as PD
is challenging, iPSC harboring monogenic, early-onset vari-
ants like PINK1 may provide valuable insights into disease
mechanisms [33]. Also critical is the capacity to generate a
significant proportion of target cells from the iPSC. In this
study, we obtained about 30% of TH+ neurons from all
genotypes.
PINK1-exon7/del mutant neurons had a significant increase in
the percentage of cells with fragmentedmitochondria suggest-
ing a shift in mitochondrial dynamics towards fission.
However, this should be interpreted with caution, because in
neurons, many different pathways can result in this pheno-
type. Indeed, we did not find any significant changes in fusion
or fission genes, besides a uniform developmental increase in
their expression.
Interestingly enough, we observed a remarkable upregula-
tion of LRRK2 in the PINK1-exon7/del mutant neurons.
Furthermore, like in fibroblasts, transient over-expression of
wild-type PINK1 effectively downregulated LRRK2 expres-
sion without having any effect on neuronal markers, mito-
chondrial dynamics, or other PARK genes.
LRRK2 has been implicated in a very broad range of
cellular pathways, and the precise mechanisms leading to
neuronal degeneration in PD-associated LRRK2 mutations
remain to be defined. Nonetheless, increased levels of
LRRK2 appear to be directly related to the pathogenicity/
toxicity of PD-related mutations, at least for the
LRRK2G2019S mutation [34], which is one of the mutations
most frequently associated with PD. Importantly, not only
mutations but also several polymorphisms in LRRK2 are
associated to an increased risk of PD. Our data suggest that
PINK1 and LRRK2 act on a common pathogenic pathway
in an antagonistic manner.
Both LRRK2 and PINK1 have been found to modulate the
phosphorylation state of several Rab GTP-ases [35, 36], and
PD-related mutations could therefore affect vesicle trafficking.
Fig. 6 LRRK2 baseline expression in PINK1 G309D fibroblasts. a
LRRK2 RNA levels analyzed by quantitative RT-PCR in fibroblasts with
PINK1 G309D homozygous mutations (N = 2) were significantly higher
than in controls (N = 5). Columns represent the mean ± SEM of three
independent experiments. *p < 0.05. b LRRK2 protein levels in the same
samples were not significantly different from control in this analyses;
experiments were done in triplicate and a representative blot is shown
above the quantification over the loading control. c Representative im-
ages of LRRK2 (green) and the mitochondrial network labeled with
MitoTracker® (magenta) in the G309D fibroblasts. Scale bar 10 μm
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In this regard, it is also interesting that over-expression of
Rab1 could rescue the SNCA mutant phenotype in inverte-
brate and mammalian models and in human neurons carrying
PD-associated SNCA triplication [37, 38], indicating that sev-
eral PARK genes with quite distinct clinical manifestations
(early onset, typical PD, or dementia with Lewy body) may
share common molecular mechanisms [39].
Further downstream, LRRK2 has recently been found to
directly phosphorylate p53 (TP53), thus acting in a pro-
apoptotic role—phosphorylation of p53 leads to transcription-
al activation of pro-apoptotic genes such as BAX, PUMA
(BBC3), NOXA (PMAIP1), and others, as well as activation
of transcriptional independent pro-apoptotic mechanisms—in
a tissue-specific manner [40]. It has been proposed that either
LRRK2 or p53 could initiate cell death in dopamine neurons
[41]. PINK1 negatively regulates p53 activity through activa-
tion (phosphorylation) of histone deacetylases, which could
account for its pro-survival and anti-apoptotic role [42].
Therefore, in PINK1 mutant neurons, the lack of functional
PINK1 could perhaps lead to activation of pro-apoptotic
mechanisms through upregulation of LRRK2, although this
remains to be proven. A better understanding of LRRK2 func-
tion is required to identify novel ways to re-establish this
balance in susceptible neurons in PINK1-associated and, per-
haps, more broadly in PD.
In conclusion, we report a novel role of PINK1 modulating
the levels of LRRK2 in patient fibroblasts and neurons.
Although LRRK2 is one of the genes that is most frequently
associated with PD, its role in early-onset recessive forms of
the disease had not been previously determined. Our results
suggest a convergent pathway for these PARK genes, acting in
an antagonistic manner, and broaden the involvement of
LRRK2 in the pathogenesis of PD.
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